General Announcement::Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
20-Jan-2022 13:42:01
Status
New
Announcement Sub Title
Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement
Announcement Reference
SG220120OTHRQRQV
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
20/01/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris Nasal Spray in for Singapore, Hong Kong and Vietnam

Attachments

PR_SGX_20012022.pdf
Total size =1328K